A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

November 29, 2025

Primary Completion Date

September 11, 2028

Study Completion Date

September 11, 2028

Conditions
Multiple MyelomaSecondary Immunodeficiency
Interventions
BIOLOGICAL

IGI, 10%

IGI, 10% IV infusion.

Trial Locations (17)

12208

New York Oncology Hematology, Albany

27834

East Carolina University, Greenville

36604

Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile

44195

Cleveland Clinic, Cleveland

48202

Henry Ford Health System, Detroit

63141

Washington University School of Medicine, St Louis

66205

University of Kansas, Westwood

92868

Chao Family Comprehensive Cancer Center UCI, Orange

Maryland

"University of Maryland , Greenebaum Cancer Center"

PE39GZ

Northwest Anglia Foundation Trust, Peterborough

EX2 5DH

Royal Devon And Exeter Hospital, Exeter

CO4 5JL

Colchester General Hospital, Colcester

GL1 3NN

Gloucestershire Royal Hospital, Gloucester

CF14 4XU

Cardiff & Vale University Health Board, Cardiff

HG2 7SX

Harrogate and District NHS Foundation Trust, Harrogate

MK6 5LD

Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes

ST16 3SA

County Hospital (Stafford Hospital), Stafford

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

collaborator

Baxalta Innovations GmbH, now part of Takeda

UNKNOWN

lead

Takeda

INDUSTRY